Rilzabrutinib, Composition of placebo is identical to that of IMP except that 400mg active ingredient is replaced with 400mg mannitol.
EFC17093
Phase 3 small_molecule active
Quick answer
Rilzabrutinib, Composition of placebo is identical to that of IMP except that 400mg active ingredient is replaced with 400mg mannitol. for Immune Thrombocytopenia (ITP) is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Immune Thrombocytopenia (ITP)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active